Febustat 40 Tablet
by Incepta Pharmaceuticals Ltd
৳13.00
Delta Pharma Limited
Febuxostat
Febuxostat is used to treat hyperuricemia in gout patients on a long-term basis. Febuxostat is not recommended for asymptomatic hyperuricemia therapy.
Febuxostat is a selective xanthine oxidase (XO) inhibitor that is non-purine. It lowers serum uric acid levels by blocking the enzyme xanthine oxidase, which produces uric acid. Xanthine oxidase converts hypoxanthine to xanthine, which is then converted to uric acid. At therapeutic dosages, Febuxostat is unlikely to inhibit other enzymes involved in purine and pyrimidine production and metabolism.
Febuxostat is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Febuxostat is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Febuxostat 80 mg is recommended. Febuxostat can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febuxostat to patients with mild to moderate renal or hepatic impairment.
When Febuxostat is taken with azathioprine, mercaptopurine, or theophylline, the plasma concentrations of these medicines may rise, resulting in severe toxicity.
Febuxostat is not recommended for people who are using azathioprine, mercaptopurine, or theophylline.
Liver function problems, nausea, arthralgia, and rash are the most prevalent side effects linked with the usage of Febuxostat.
There are no sufficient and well-controlled trials in pregnant women in pregnancy category C. Only if the possible benefit outweighs the risk to the fetus should Febuxostat be used during pregnancy. This medication is not known to be excreted in human milk. When given to a breastfeeding mother, Febuxostat should be used with caution.
Gout Flare: When anti-hyperuricemic drugs, such as Febuxostat, are first started, an increase in gout flares is common. Febuxostat does not need to be stopped if gout flares up during treatment. For up to six months, prophylactic therapy (i.e., nonsteroidal anti-inflammatory medicine (NSAID) or colchicine at the start of treatment) may be effective.
Cardiovascular Events: In clinical trials, patients treated with febuxostat had a greater rate of cardiovascular thromboembolic events than those treated with allopurinol. Keep an eye out for signs and symptoms of a heart attack or a stroke.
Transaminase Elevation: In febuxostat-treated patients, transaminase levels have been found to be elevated. Regularly check your liver function tests.
Medications are used to treat gout.
Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.
Delta Pharma Ltd.
by Aristopharma Ltd.
৳11.00